Most of what circulates about SLU-PP-332 online concerns fat loss and endurance — the "exercise in a pill" framing that followed the 2023 ACS Chemical Biology paper. But if you rank the animal evidence by how hard the experiments were, the single most rigorous in vivo dataset on this compound isn't about running wheels or body fat at all. It's a 2024 Circulation paper in which mice with surgically failing hearts were dosed twice daily by injection. That study is where a lot of the mechanistic detail lives — and where the most useful cautions live too. Here's what SLU-PP-332 research actually shows, why the cardiac data cuts both ways, and where the compound sits legally in Australia.

For the compound's background, chemistry and dosing literature, see our SLU-PP-332 profile.

What Is SLU-PP-332? Start by Correcting the Category

SLU-PP-332 is not a peptide. It is a synthetic small molecule — a pan-agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, a family of orphan nuclear receptors that regulate mitochondrial biogenesis and oxidative metabolism. It came out of Thomas Burris's laboratory and is routinely mis-filed under "peptides" simply because it's sold through the same grey channels as research peptides. The distinction matters: dosing logic, stability assumptions and metabolism all differ from a peptide.

It also has poor oral bioavailability, which is why the same group engineered a successor, SLU-PP-915, as the orally active pan-ERR agonist. Anything marketed as an "oral SLU-PP-332" is working against the pharmacokinetics its own inventors published.

The Study Most Summaries Skip: A Failing Mouse Heart

In January 2024, researchers at Baylor College of Medicine and collaborators published a study in Circulation testing both SLU-PP-332 and SLU-PP-915 in a transaortic constriction (TAC) model — a surgical pressure-overload procedure that drives mice into heart failure.

What was reported

Both compounds improved ejection fraction, reduced cardiac fibrosis and increased survival in the pressure-overloaded animals, without changing the degree of cardiac hypertrophy. RNA sequencing and metabolomics showed broad activation of metabolic gene programs, with normalisation of fatty-acid, lipid and TCA/oxidative-phosphorylation metabolite profiles in the failing heart. The framing is "metabolic rescue": a failing heart shifts its fuel use, and ERR agonism pushes it back toward fatty-acid oxidation and mitochondrial capacity.

The isoform twist

Genetic dependency experiments in that paper pointed to ERRγ as the main mediator of the cardioprotective transcriptional response. That's a meaningful departure from the exercise-capacity story, where the acute aerobic response to SLU-PP-332 was reported as ERRα-dependent. Same molecule, different receptor doing the work in different tissues — which is exactly what you'd expect from a pan-agonist, and exactly why "it boosts ERR" is not a usable model of what happens in a whole body.

The dose nobody quotes

The reported regimen in that model was 25 mg/kg intraperitoneally, twice daily. That is an injected, high-frequency, milligram-per-kilogram regimen in a mouse with a surgically constricted aorta. It is not a protocol, it is not translatable by simple arithmetic to humans, and no human equivalent has been established because no human has been dosed.

Why the Cardiac Findings Cut Both Ways

It's tempting to read "improved ejection fraction and survival" as a bonus safety signal. It isn't. What the Circulation work actually demonstrates is that systemic pan-ERR agonism reaches and remodels cardiac gene expression and cardiac fuel handling. A drug potent enough to rewire the metabolism of a diseased heart is a drug with cardiac effects in everyone who takes it — including people with undiagnosed cardiomyopathy, arrhythmia or ischaemic disease, and including people stacking stimulants or thyroid hormone.

Three honest limits on the cardiac literature:

  • Model-specific. Pressure overload from aortic constriction is one aetiology. Most human heart failure is ischaemic, hypertensive, diabetic or HFpEF — different biology, untested here.
  • Short horizon. These are weeks-long rodent experiments. Chronic ERR activation, tumour biology (ERRα is studied as a pro-tumourigenic factor in several cancers) and reproductive endpoints are not resolved by them.
  • Commercial interest. ERR agonists are being pursued commercially by companies connected to the originating chemists. That doesn't invalidate anything, but read the conflict-of-interest declarations on the primary papers rather than press summaries.

A 2026 review of ERR agonist pharmacology in RSC Chemical Biology places SLU-PP-332 firmly in the tool-compound category: valuable for interrogating receptor biology, not a candidate with a human safety package.

Is SLU-PP-332 Legal in Australia?

The short answer: it is unscheduled, and that is not the same as legal to use.

  • SLU-PP-332 is not listed by name in the Poisons Standard. The SR9009 entry that people sometimes cite covers REV-ERB agonists — a different receptor family and a different compound class. It does not capture SLU-PP-332.
  • There is no TGA-approved product containing it, no ARTG entry, and therefore no lawful pathway for therapeutic supply in Australia. Compounds sold "for research use only" are not supplied for human administration, and importing or using them that way sits outside the therapeutic goods framework entirely.
  • Sport is unambiguous. WADA's S0 catch-all prohibits any substance not approved by a government regulatory health authority for human therapeutic use. SLU-PP-332 meets that definition squarely. Anti-doping laboratories published metabolism and detection methodology for it in 2026 — the drug test now exists, even though the clinical trial never has.

For the broader Australian regulatory picture across this space, see our peptides section.

Where the Australian relevance genuinely sits

It's in the target population, not the product. Heart failure is not a niche problem here — the Heart Foundation reports roughly 146,000 Australian adults living with heart failure, with prevalence rising sharply past age 75. Metabolic therapies for the failing heart are a legitimate unmet need, and ERR agonism is a defensible hypothesis for it. That's an argument for funding the clinical program, not for self-experimentation with the prototype.

What Would Actually Move This Forward

A Phase 1 in humans. There isn't one. As of September 2026 there are no registered human trials of SLU-PP-332 or SLU-PP-915 from a verifiable sponsor — and if you go looking on trial registries, check the sponsor is a real organisation before you believe an entry. Until first-in-human safety, pharmacokinetics and a defined dose range exist, every number attached to this compound is a mouse number.

Want the updates when that changes? Join the free list — we flag new primary literature and regulatory movement as it lands.

FAQ

Is SLU-PP-332 a peptide?

No. SLU-PP-332 is a synthetic small molecule that activates the estrogen-related receptors ERRα, ERRβ and ERRγ. It is commonly mislabelled as a peptide because it is sold through similar channels.

What does SLU-PP-332 research actually show?

In mice, it increases exercise capacity, alters fat metabolism, and — in a 2024 Circulation study using a surgical pressure-overload model — improved ejection fraction, reduced fibrosis and increased survival. All findings are preclinical and animal-only.

Is SLU-PP-332 legal in Australia?

It is not listed in the Poisons Standard, but there is no TGA-approved product and no lawful pathway for therapeutic supply. It is also prohibited in sport under WADA's S0 catch-all category.

Has SLU-PP-332 been tested in humans?

No. There are no completed or registered human trials from a verifiable sponsor, and no established human dose, safety profile or efficacy data.

Sources

This article is independent information, not medical advice. SLU-PP-332 is an investigational research compound with no approval from the TGA or any comparable regulator, no human trial data, and no lawful therapeutic supply in Australia; speak to a qualified Australian health practitioner about your own care.